With over 40 years of experience in Research & Development, Dr. Peter Bernardo has been instrumental in initiating and accommodating tremendous changes in the pharmaceutical industry.

In 2001, Dr. Bernardo founded Xerimis Inc. with the sole purpose of providing customized clinical packaging services to this evolving industry. Dr. Bernardo developed Xerimis’ experienced staff and premier cGMP facility as keys to accommodating trial designs ranging from the straightforward to the most highly complex.

Prior to the formation of Xerimis Inc. in 2001, Dr. Bernardo founded and successfully guided Simirex Inc. (also dedicated to contract packaging and labeling of clinical supplies) through exponential growth during its ten-year existence (1988-1998), until its acquisition by Quintiles Transnational Inc., one of the largest clinical research organizations in the world. Dr. Bernardo served Quintiles as Chief Operating Officer, Worldwide Clinical Supplies, from 1998 through 2000. Earlier, as Vice President of the Flint Division of Baxter Travenol, Dr. Bernardo was involved in all aspects of development and production activities. Prior to that, he was Formulation Development Head at Lederle Laboratories, with responsibility for both prescription and OTC product formulation. Dr. Bernardo was also formerly at SmithKline and Parke-Davis, where he gained experience in manufacturing and clinical supply production, labeling and packaging.

Dr. Bernardo received his BS in Pharmacy from Duquesne University and his MS and Ph.D. from the University of Michigan.

Dr. Bernardo has been a member of the Dean’s Steering Committee of the College of Pharmacy at the University of Michigan. He is a member of AAPS, DIA, APhA, ISPE, Rho Chi, Phi Lambda Upsilon and Sigma XI.